Abstract
The efficacy of two regimens of oral enoxacin (400 mg as a single dose or two 200 mg doses 12 hours apart) to treat anal and pharyngeal gonorrhoea was compared. Fifty men with confirmed gonorrhoea (40 with anal, six with pharyngeal, and four with both) were treated and assessed three to five and seven to 14 days after treatment. Of 44 evaluable patients who attended the first follow up, including those who were infected with penicillinase producing Neisseria gonorrhoeae (PPNG), all were cured. No haematological or biochemical abnormality associated with enoxacin was observed. Nine patients reported minor adverse effects during the trial period, only one of which was considered probably related to the treatment. Both regimens of 400 mg enoxacin were effective in treating anal and pharyngeal gonorrhoea.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Davies B. I., Maesen F. P., Teengs J. P. Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study. J Antimicrob Chemother. 1984 Sep;14 (Suppl 100):83–89. doi: 10.1093/jac/14.suppl_c.83. [DOI] [PubMed] [Google Scholar]
- Honeybourne D., Wise R., Andrews J. M. Ciprofloxacin penetration into lungs. Lancet. 1987 May 2;1(8540):1040–1040. doi: 10.1016/s0140-6736(87)92315-4. [DOI] [PubMed] [Google Scholar]
- Hook E. W., 3rd, Holmes K. K. Gonococcal infections. Ann Intern Med. 1985 Feb;102(2):229–243. doi: 10.7326/0003-4819-102-2-229. [DOI] [PubMed] [Google Scholar]
- Shahmanesh M., Shukla S. R., Phillips I., Westwood A., Thin R. N. Ciprofloxacin for treating urethral gonorrhoea in men. Genitourin Med. 1986 Apr;62(2):86–87. doi: 10.1136/sti.62.2.86. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wagenvoort J. H., van der Willigen A. H., van Vliet H. J., Michel M. F., Van Klingeren B. Resistance of Neisseria gonorrhoeae to enoxacin. J Antimicrob Chemother. 1986 Sep;18(3):429–429. doi: 10.1093/jac/18.3.429. [DOI] [PubMed] [Google Scholar]
- Wise R., Andrews J. M., Danks G. In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents. J Antimicrob Chemother. 1984 Mar;13(3):237–244. doi: 10.1093/jac/13.3.237. [DOI] [PubMed] [Google Scholar]